Rivista di formazione e aggiornamento professionale del pediatra e del medico di base, dal 1982 In collaborazione con l'Associazione Culturale Pediatri

Il punto su

PDF MeBrain

Linfoma di Burkitt in età pediatrica

Burkitt lymphoma in Paediatrics

Fabio Timeus1,2, Matilde Piglione2, Franca Fagioli2, Aldo Ravaglia3
1UOC di Pediatria e Neonatologia, Ospedale di Chivasso, ASL TO4, Torino
2Onco-Ematologia Pediatrica, Centro Trapianti e Terapia Cellulare, Ospedale Infantile “Regina Margherita”, Torino
3Pediatra di famiglia, Chivasso (Torino)

Giugno 2021 | DOI: 10.53126/MEBXXIV175

Abstract
Sporadic Burkitt lymphoma (BL) accounts for about 80% of non-Hodgkin lymphomas in childhood and adolescence, with an incidence of 3-5 cases per million in developed countries. The hallmark of LB is the deregulation of MYC oncogene, usually caused by the [t(8;14)(q24;q32)] translocation, involving the gene of immunoglobulin heavy chain. BL is a very aggressive neoplasm, with a doubling time of 12-24 hours and its diagnosis and therapy are a true haematologic emergency. Abdomen, head and neck are the most frequent sites of presentation and the involvement of ileo-caecal area can cause an intussusception as first manifestation of the disease.
BL and mature B-cell acute leukaemia (the leukaemic manifestation of BL) share the same therapeutic approach, intensive short courses with multiple alternating chemotherapy agents, the use of high dose-methotrexate and intrathecal CNS prophylaxis. The outcomes are satisfactory: in Italy during the period 1997-2014 the children with BL were treated according to the AIEOP LNH-97 protocol, achieving more than 90% of 5 year-survival.
In the last decades, the prognosis for children and adolescents with cancer has dramatically improved and the increasing number of long-term survivors has focused the attention of clinicians on the late effects of cancer and its therapy. A multidisciplinary follow up and a correct transition from the paediatrician to the primary care doctor plays a central role not only in the early detection and therapy of late effects of cancer but also in supporting the patient to realize their physical, mental and social well-being as much as possible.
Contenuto riservato

Per leggere l'articolo è necessario effettuare il login.

Per l'acquisto del singolo articolo scrivi a abbonamenti@medicoebambino.com (la mail si prepara da sola con gli estremi dell'articolo); se accedi, la richiesta parte con un click.

Bibliografia

  1. Burkitt D. A sarcoma involving the jaws in African children. Br J Surg 1958;46(197):218-23. DOI: 10.1002/bjs.18004619704.
  2. Dunleavy K, Little RF, Wilson WH. Update on Burkitt lymphoma. Hematol Oncol Clin N Am 2016;30:1333-43. DOI: 10.1016/j.hoc.2016.07.009.
  3. Swerdlow SH, Campo E, Harris NL, et al. (eds). WHO classification of tumors of haematopoietic and lymphoid tissues. Revised 4th edition. IARC Press, 2017.
  4. Swerdlow SH, Campo E, Harris NL, et al. (eds). WHO classification of tumors of haematopoietic and lymphoid tissues. Lyon, France: IARC, 2008.
  5. Dalla Favera R, Bregni M, Erikson J, Patterson J, Gallo RC, Wong-Staal F. Human c-myc oncogene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. Proc Natl Acad Sci USA 1982;79(24):7824-7. DOI: 10.1073/pnas.79.24.7824.
  6. Love C, Sun Z, Jima D, et al. The genetic landscape of mutations in Burkitt lymphoma. Nat Genet 2012;44(12):1321-5. DOI: 10.1038/ng.2468.
  7. Kelly GL, Rickinson AB. Burkitt lymphoma: revisiting the pathogenesis of a virus-associated malignancy. Hematology Am Soc Hematol Educ Program 2007;277-84. DOI: 10.1182/asheducation-2007.1.277.
  8. Shiramizu B, Barriga F, Neequaye J, et al. Patterns of chromosomal breakpoint locations in Burkitt’s lymphoma: relevance to geography and Epstein-Barr virus association. Blood 1991;77:1516-26.
  9. Mbulaiteye SM, Biggar RJ, Bhatia K, Linet MS, Devesa SS. Sporadic childhood Burkitt lymphoma incidence in United States during 1992-2005. Pediatric Blood and Cancer 2009;53:366-70. DOI: 10.1002/pbc.22047.
  10. Magrath IT. African Burkitt’s lymphoma. History, biology, clinical features, and treatment. Am J Pediatr Hematol Oncol 1991;13:222-46.
  11. Pillon M, Mussolin L, Carraro E, et al. Detection of prognostic factors in children and adolescents with Burkitt and diffuse large B-cell lymphoma treated with the AIEOP LNH-97 protocol. Br J Haematol 2016;175(3):467-475. DOI: 10.1111/bjh.14240.
  12. Murpy SB. Classification, staging and results of treatment of childhood non-Hodgkin’s lymphomas: dissimilarities from lymphomas in adults. Semin Oncol 1980;7:332-39.
  13. Rosolen A, Perkins SL, Pinkerton R, et al. Revised international pediatric non-Hodgkin lymphoma staging system. Journal of Clinical Oncology 2015;33(18):2112-20. DOI: 10.1200/JCO.2014.59.7203.
  14. Reiter A, Schrappe M, Tienmann M, et al. Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: a report of Berlin-Frankfurt-Munster Group Trial NHL-BFM 90. Blood 1999;94(10):3294-306.
  15. Woessmann W, Seidemann K, Mann G, et al. The impact of methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: a report of the BFM Group Study NHL-BFM95. Blood 2005;105:948-58. DOI: 10.1182/blood-2004-03-0973.
  16. Cairo MS, Gerrard M, Sposto R, et al. Results of randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents. Blood 2007;109:2736-43. DOI: 10.1182/blood-2006-07-036665.
  17. Minard-Colin V, Brugieres L, Reiter A, et al. Non Hodgkin lymphoma in children and adolescents: progress through effective collaboration, current knowledge, and challenges ahead. Journal of Clinical Oncology 2015;33:2963-74. DOI: 10.1200/JCO.2014.59.5827.
  18. Cairo MS, Pinkerton R. Childhood, adolescent and young adult non-Hodgkin lymphoma: state of the science. Br J Haematol 2016;173(4):507-30. DOI: 10.1111/bjh.14035.
  19. Egan G, Goldman S, Alexander S. Mature B-NHL in children, adolescent and young adults: current therapeutic approach and emerging treatment strategies. Br J Haematol 2019;185(6):1071-1085. DOI: 10.1111/bjh.15734.
  20. Minard-Colin V, Auperin A, Pillon M, et al. Results of the randomized Intergroup trial Inter-B-NHL Ritux 2010 for children and adolescents with high-risk B-cell non-Hodgkin lymphoma (B-NHL) and mature acute leukemia (B-AL): evaluation of rituximab (R) efficacy in addition to standard LMB chemotherapy (CT) regimen. Journal of Clinical Oncology 2016;34:10507. DOI: 10.1200/JCO.2016.34.15_suppl.10507.
  21. Mussolin L, Lovisa F, Gallingani I, et al. Minimal residual disease analysis in childhood mature B-cell leukaemia/lymphoma treated with AIEOP LNH-97 protocol with/without anti-CD20 administration. Br J Haematol 2020;189(3):e108-11. DOI: 10.1111/bjh.16531.
  22. Anoop P, Sankpal S, Stiller C, et al. Outcome of childhood relapsed or refractory mature B-cell non-Hodgkin lymphoma and acute lymphoblastic leukemia. Leuk Lymphoma 2012;53:1882-88. DOI: 10.3109/10428194.2012.677534.
  23. Jourdain A, Auperin A, Minard-Colin V, et al. Outcome and prognostic factors for relapse in children and adolescents with mature B-cell lymphoma and leukemia treated in three consecutive prospective “Lymphomes Malins B” protocols. A Societé Francaise des Cancers de l’Enfant study. Haematologica 2015;100(6):810-7. DOI: 10.3324/haematol.2014.121434.
  24. Griffin TC, Weitzman S, Weinstein H, et al. A study of rituximab and ifosfamide, carboplatin, and etoposide chemotherapy in children with recurrent/refractory B-cell (CD20+) non-Hodgkin lymphoma and mature B-cell acute lymphoblastic leukemia: a report from the Children’s Oncology Group. Pediatr Blood Cancer 2009;52(2):177-81. DOI: 10.1002/pbc.21753.
  25. Giulino-Roth L, Ricafort R, Kernan NA, et al. Ten-year follow up of pediatric patients with non-Hodgkin lymphoma treated with allogeneic or autologous stem cell transplantation. Pediatr Blood Cancer 2013;60(12):2018-24. DOI: 10.1002/pbc.24722.
  26. Rivers J, Annesley C, Summers C, et al. Early response data for pediatric patients with non-Hodgkin lymphoma treated with CD19 chimeric antigen receptor (CAR) T-cells. Blood 2018;132 (Supplement 1):2957. DOI: 10.1182/blood-2018-99-113744.
  27. Tolani B, Gopalakrishnan R, Punj V, Matta H, Chaudhary PM. Targeting MYC in KSHV-associated primary effusion lymphoma with BET bromodomain inhibitors. Oncogene 2014;33(22):2928-37. DOI: 10.1038/onc.2013.242.
  28. Bhadury J, Nilsson LM, Veppil Muralidharan S, et al. BET and HDAC inhibitors induce similar genes and biological effects and synergize to kill in Myc-induced murine lymphoma. Proc Natl Acad Sci USA 2014;111(26):E2721-30. DOI: 10.1073/pnas.1406722111.
  29. Gupta H, Davidoff AM, Pui CH, Shochat SJ, Sandlund JT. Clinical implications and surgical management of intussusception in pediatric patients with Burkitt lymphoma. J Pediatr Surg 2007;42(6):998-1001; discussion 1001. DOI: 10.1016/j.jpedsurg.2007.01.033.
  30. Wayne ER, Campbell JB, Kosloske AM, Burrington JD. Intussusception in the older child- suspect lymphosarcoma. J Pediatr Surg 1976;11(5):789-94. DOI: 10.1016/0022-3468(76)90104-4.
  31. Kulendran K, Choy KT, Keogh C, Ratnapala D. An Exceptional Case of Ileocolic Intussusception Secondary to Burkitt’s Lymphoma: What Variations Are There in the Presentation and Management of Those Patients Who Approach Adolescence? Case Rep Surg 2018;2018:6251321. DOI: 10.1155/2018/6251321.
  32. Mimery AH, Jabbour J, Sykes B, MacDermid E, Al-Askari M, De Clercq S. Burkitt leukemia presenting as acute appendicitis: a case report and literature review. Am J Case Rep 2020;21:e921568. DOI: 10.12659/AJCR.921568.
  33. Gatta G, Botta L, Rossi S, et al.; EUROCARE Working Group. Childhood cancer survival in Europe 1999-2007: results of EUROCARE-5 - a population-based study. Lancet Oncol 2014;15(1):35-47. DOI: 10.1016/S1470-2045(13)70548-5.
  34. Michel G, Mulder RL, van der Pal HJH, et al. Evidence-based recommendations for the organization of long-term follow-up care for childhood and adolescent cancer survivors: a report from the PanCareSurFup Guidelines Working Group. J Cancer Surviv 2019;13(5):759-72. DOI: 10.1007/s11764-019-00795-5.
  35. Jankovic M, Haupt R, Spinetta JJ, et al., participants in PanCare. Long-term survivors of childhood cancer: cure and care-the Erice Statement (2006) revised after 10 years (2016) . J Cancer Surviv 2018;12(5):647-50. DOI: 10.1007/s11764-018-0701-0.
  36. Jankovic M, Fraschini D, Nova G. Ragazzi guariti da tumore pediatrico: una realtà in continua crescita. Quaderni acp 2019;2:67-73.
  37. Gupta A, Moore JA. Tumor lysis syndrome. JAMA Oncol 2018;4(6):895. DOI: 10.1001/jamaoncol.2018.0613.
  38. Rahmani B, Patel S, Seyam O, et al. Current understanding of tumor lysis syndrome. Hematol Oncol 2019;37(5):537-47. DOI: 10.1002/hon.2668.
  39. Wössmann W, Schrappe M, Meyer U, Zimmermann M, Reiter A. Incidence of tumor lysis syndrome in children with advanced stage Burkitt’s lymphoma/leukemia before and after introduction of prophylactic use of urate oxidase. Ann Hematol 2003;82(3):160-5. DOI: 10.1007/s00277-003-0608-2.
  40. Barrington SF, Mikhaeel NG, Kostakoglu L, et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol 2014;32(27):3048-58. DOI: 10.1200/JCO.2013.53.5229.
  41. Karantanis D, Durski JM, Lowe VJ, et al. 18F-FDG PET and PET/CT in Burkitt’s lymphoma. Eur J Radiol 2010;75(1):e68-73. DOI: 10.1016/j.ejrad.2009.07.035.
  42. Sandlund JT. Burkitt lymphoma: staging and response evaluation. Br J Haematol 2012;56(6):761-5. DOI: 10.1111/j.1365-2141.2012.09026.x.
  43. Bailly C, Eugène T, Couec ML, et al. Prognostic value and clinical impact of (18)FDG-PET in the management of children with Burkitt lymphoma after induction chemotherapy. Front Med (Lausanne) 2014;1:54. DOI: 10.3389/fmed.2014.00054.
  44. Furth C, Steffen IG, Erdrich AS, et al. Explorative analyses on the value of interim PET for prediction of response in pediatric and adolescent non-Hodgkin lymphoma patients. EJNMMI Res 2013;3(1):71. DOI: 10.1186/2191-219X-3-71.
  45. Riad R, Omar W, Sidhom I, et al. False-positive F-18 FDG uptake in PET/CT studies in pediatric patients with abdominal Burkitt’s lymphoma. Nucl Med Commun 2010;31(3):232-8. DOI: 10.1097/MNM.0b013e328334fc14.
  46. Carrillo-Cruz E, Marín-Oyaga VA, Solé Rodríguez M, et al. Role of 18F-FDG-PET/CT in the management of Burkitt lymphoma. Eur J Haematol 2015;94(1):23-30. DOI: 10.1111/ejh.12284.